These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 18408903)

  • 21. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
    Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
    J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ebselen effects on MPTP-induced neurotoxicity.
    Dhanasekaran M; Uthayathas S; Karuppagounder SS; Parameshwaran K; Suppiramaniam V; Ebadi M; Brown-Borg HM
    Brain Res; 2006 Nov; 1118(1):251-4. PubMed ID: 16956591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?
    Castagnoli K; Murugesan T
    Neurotoxicology; 2004 Jan; 25(1-2):279-91. PubMed ID: 14697903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase.
    Corsini GU; Pintus S; Bocchetta A; Piccardi MP; Del Zompo M
    J Pharmacol Exp Ther; 1986 Aug; 238(2):648-52. PubMed ID: 3488394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective inhibition of MAO-B through chronic low-dose (R)-deprenyl treatment in C57BL/6 mice has no effect on basal neostriatal dopamine levels.
    Steyn SJ; Castagnoli K; Steyn S; Castagnoli N
    Exp Neurol; 2001 Apr; 168(2):434-6. PubMed ID: 11259132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neural progenitor cells are protected against MPTP by MAO-B inhibitors.
    He XJ; Uetsuka K; Nakayama H
    Neurotoxicology; 2008 Nov; 29(6):1141-6. PubMed ID: 18606181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice.
    Perez V; Unzeta M
    Neurochem Int; 2003 Feb; 42(3):221-9. PubMed ID: 12427476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
    Quik M; Parameswaran N; McCallum SE; Bordia T; Bao S; McCormack A; Kim A; Tyndale RF; Langston JW; Di Monte DA
    J Neurochem; 2006 Sep; 98(6):1866-75. PubMed ID: 16882311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
    Hamaue N; Minami M; Terado M; Hirafuji M; Endo T; Machida M; Hiroshige T; Ogata A; Tashiro K; Saito H; Parvez SH
    Neurotoxicology; 2004 Jan; 25(1-2):205-13. PubMed ID: 14697895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice.
    Araki T; Kumagai T; Matsubara M; Ido T; Imai Y; Itoyama Y
    Metab Brain Dis; 2000 Sep; 15(3):193-201. PubMed ID: 11206588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apomorphine protects against MPTP-induced neurotoxicity in mice.
    Grünblatt E; Mandel S; Berkuzki T; Youdim MB
    Mov Disord; 1999 Jul; 14(4):612-8. PubMed ID: 10435498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
    Kawasaki T; Ago Y; Kitao T; Nashida T; Takagi A; Takuma K; Matsuda T
    Neuropharmacology; 2008 Oct; 55(5):654-60. PubMed ID: 18573265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
    Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X
    Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deuterium isotope effects for the oxidation of 1-methyl-3-phenyl-3-pyrrolinyl analogues by monoamine oxidase B.
    Pretorius A; Ogunrombi MO; Terre'blanche G; Castagnoli N; Bergh JJ; Petzer JP
    Bioorg Med Chem; 2008 Oct; 16(19):8813-7. PubMed ID: 18799315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.
    Geldenhuys WJ; Darvesh AS; Funk MO; Van der Schyf CJ; Carroll RT
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5295-8. PubMed ID: 20650633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulating effect of Hypericum perforatum extract on astrocytes in MPTP induced Parkinson's disease in mice.
    Mohanasundari M; Sabesan M
    Eur Rev Med Pharmacol Sci; 2007; 11(1):17-20. PubMed ID: 17405345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.